Skip to main content

Table 2 The methodological quality evaluation of included literature based on AHRQ

From: A meta-analysis of the incidence rate of postoperative acute kidney injury in patients with congenital heart disease

Study Year A B C D E F G H I J K Total Scores
Chen Ya-ke 2011 1 1 1 1 1 0 1 0 0 1 0 7
Dong Yu-fu 2005 1 1 1 1 0 1 1 0 0 1 0 7
Blinder, JJ 2017 1 1 1 1 0 0 1 0 1 1 1 8
Fuhrman, DY 2019 1 1 1 1 0 1 1 0 0 1 0 7
Garcia, RU 2020 1 1 1 1 0 0 1 0 0 1 1 7
Gil-Ruiz Gil-Esparza 2014 1 1 1 1 0 1 1 0 0 1 0 7
Hirano, D 2017 1 1 1 1 1 0 1 0 0 1 0 7
Huggins, N 2014 1 1 1 1 0 1 0 0 0 1 0 6
Joffe, R 2018 1 1 1 1 1 0 1 1 0 1 0 8
Kim, J 2020 1 1 1 1 0 1 0 0 0 1 0 6
Kimura, S 2018 1 1 1 1 1 0 1 0 0 1 0 7
Kumar, TK 2016 1 1 1 1 0 0 0 0 1 1 0 6
Kwiatkowski, DM 2017 1 1 1 1 0 1 1 0 0 1 1 8
Lee, SH 2017 1 1 1 1 1 0 1 0 0 1 0 7
Li, S 2011 1 1 1 1 0 0 1 0 0 1 0 6
Madsen, NL 2017 1 1 1 1 0 0 1 0 0 1 0 6
Mah, KE 2018 1 1 1 1 1 0 1 0 0 1 0 7
Meersch, M 2014 1 1 1 1 0 0 1 0 0 1 0 6
Miklaszewska, M 2013 1 1 1 1 0 1 1 0 0 1 0 7
Park, SK 2016 1 1 1 1 0 0 1 0 0 1 0 6
Piggott, KD 2015 1 1 1 1 1 0 1 0 0 1 0 7
Ricci, Z 2012 1 1 1 1 0 0 0 0 0 1 0 5
Ruf, B 2015 1 1 1 1 0 0 1 0 0 1 0 6
Sugimoto, K 2016 1 1 1 1 0 1 0 1 0 1 0 7
Tanyildiz, M 2017 1 1 1 1 0 0 1 0 0 1 0 6
Taylor, ML 2013 1 1 1 1 1 0 1 0 0 1 0 7
Toth, R 2012 1 1 1 1 0 0 1 0 0 1 0 6
Ueno, K 2020 1 1 1 1 0 0 1 0 0 1 0 6
Van Driest, SL 2018 1 1 1 1 0 1 1 0 0 1 1 8
Zheng, J 2013 1 1 1 1 0 0 1 0 0 1 0 6
  1. A: Define the source of information (survey, record review); B: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; C: Indicate time period used for identifying patients; D: Indicate whether or not subjects were consecutive if not population-based; E: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; F: Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements); G: Explain any patient exclusions from analysis; H:Describe how confounding was assessed and/or controlled; I: If applicable, explain how missing data were handled in the analysis; J: Summarize patient response rates and completeness of data collection; K: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained
\